{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:03:38Z","timestamp":1775847818278,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jaapos.2011.11.002","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T18:46:44Z","timestamp":1326221204000},"page":"2-4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?"],"prefix":"10.1016","volume":"16","author":[{"given":"Robert L.","family":"Avery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2011.11.002_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaapos.2011.11.002_bib2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: Incorporating the BEAT-ROP results into clinical practice","volume":"118","author":"Moshfeghi","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2011.11.002_bib3","doi-asserted-by":"crossref","unstructured":"Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Epub ahead of print Dec 30 2011. Arch Dis Child Fetal Neonatal Ed.","DOI":"10.1136\/archdischild-2011-301148"},{"key":"10.1016\/j.jaapos.2011.11.002_bib4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaapos.2011.11.002_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jaapos.2011.11.002_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/eye.2011.66","article-title":"Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab","volume":"25","author":"Meyer","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jaapos.2011.11.002_bib7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2011.11.002_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaapos.2009.03.006","article-title":"Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema","volume":"13","author":"Al-Dhibi","year":"2009","journal-title":"J AAPOS"},{"key":"10.1016\/j.jaapos.2011.11.002_bib9","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/IAE.0b013e318213da43","article-title":"Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema","volume":"31","author":"Acharya","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2011.11.002_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials","volume":"149","author":"Barbazetto","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2011.11.002_bib11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2011.11.002_bib12","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.09-4140","article-title":"Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes","volume":"51","author":"Miyake","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaapos.2011.11.002_bib13","first-page":"329","article-title":"Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern","volume":"13","author":"Avery","year":"2009","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2011.11.002_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10792-008-9221-7","article-title":"Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: Preliminary findings of a pilot study","volume":"29","author":"Ziemssen","year":"2009","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jaapos.2011.11.002_bib15","unstructured":"Sato T, Wada K, Arahori H, et\u00a0al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Epub ahead of print Sep 17, 2011. Am J\u00a0Ophthalmol."},{"key":"10.1016\/j.jaapos.2011.11.002_bib16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bjo.2008.156810","article-title":"Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab","volume":"94","author":"Matsuyama","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2011.11.002_bib17","first-page":"161","article-title":"Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in\u00a0eyes with proliferative diabetic retinopathy","volume":"31","author":"Qian","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2011.11.002_bib18","unstructured":"Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Epub ahead of print Oct 7, 2011. Am J\u00a0Ophthalmol."},{"key":"10.1016\/j.jaapos.2011.11.002_bib19","doi-asserted-by":"crossref","unstructured":"Carneiro AM, Costa R, Falc\u00e3o MS, et\u00a0al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Epub ahead of print Sep 29, 2011. Acta Ophthalmol.","DOI":"10.1111\/j.1755-3768.2011.02240.x"},{"key":"10.1016\/j.jaapos.2011.11.002_bib20","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2009.05.020","article-title":"Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor","volume":"116","author":"Miki","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2011.11.002_bib21","first-page":"2803","article-title":"FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye","volume":"15","author":"Kim","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.jaapos.2011.11.002_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bjo.2007.128371","article-title":"VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity","volume":"92","author":"Pieh","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2011.11.002_bib23","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1167\/iovs.10-6798","article-title":"Effect of VEGF trap\u00a0on normal retinal vascular development and oxygen-induced retinopathy in the dog","volume":"52","author":"Lutty","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaapos.2011.11.002_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbrc.2011.04.014","article-title":"Comparing protein VEGF inhibitors: In\u00a0vitro biological studies","volume":"408","author":"Yu","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaapos.2011.11.002_bib25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI10259","article-title":"Inhibition of VEGF receptors causes lung cell apoptosis and emphysema","volume":"106","author":"Kasahara","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaapos.2011.11.002_bib26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nm721","article-title":"Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice","volume":"8","author":"Compernolle","year":"2002","journal-title":"Nat Med"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853111006124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853111006124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:17:54Z","timestamp":1761077874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853111006124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1091853111006124"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2011.11.002","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2011.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}